Antigens, CD274

• 

  Subject Areas on Research

  • A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer. 
  • A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. 
  • A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes. 
  • A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. 
  • Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. 
  • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. 
  • Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients. 
  • An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1. 
  • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. 
  • Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. 
  • Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. 
  • B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. 
  • B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. 
  • B7-h1 as a biomarker for therapy failure in patients with favorable histology Wilms tumor. 
  • CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. 
  • Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. 
  • Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. 
  • Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. 
  • Combinations of Bevacizumab With Cancer Immunotherapy. 
  • Comprehensive Characterization of Cancer Driver Genes and Mutations. 
  • Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. 
  • Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. 
  • Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma? 
  • Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. 
  • Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. 
  • Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. 
  • Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. 
  • Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy. 
  • First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. 
  • First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. 
  • Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. 
  • Functional CD3+CD8+PD1- T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast. 
  • Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. 
  • Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark? 
  • Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. 
  • Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management. 
  • Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. 
  • Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. 
  • Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. 
  • Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. 
  • Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer. 
  • Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. 
  • In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. 
  • Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. 
  • Irradiation and immunotherapy: From concept to the clinic. 
  • Long-term surviving influenza infected cells evade CD8+ T cell mediated clearance. 
  • Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. 
  • Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. 
  • Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. 
  • Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. 
  • Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. 
  • Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. 
  • PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. 
  • PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. 
  • PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. 
  • PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. 
  • PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes. 
  • PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. 
  • PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. 
  • PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation. 
  • PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. 
  • Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. 
  • Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas. 
  • Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors. 
  • Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma. 
  • Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. 
  • STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. 
  • Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. 
  • Soluble B7-H1: differences in production between dendritic cells and T cells. 
  • Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma. 
  • Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. 
  • Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). 
  • Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. 
  • Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. 
  • The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation. 
  • The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. 
  • Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. 
  • Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. 
  • Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas. 
  • Update: biomarkers for idiopathic inflammatory myopathies.